Cardio Diagnostics Holdings, Inc. reported nominal revenue growth to $14,825 with continued significant net losses as of the end of 2025, per its May 2026 quarterly filing. The company leverages its proprietary AI-driven Multi-Omics Engine™ integrating genetic and epigenetic biomarkers to develop differentiated cardiovascular diagnostic tests targeting multiple healthcare stakeholders. While reimbursement code achievements and international expansion into markets like India provide growth avenues, commercialization cycles remain prolonged with regulatory and competitive hurdles. Liquidity is supported by a high current ratio despite zero cash holdings, underscoring working capital sufficiency but signaling ongoing financing needs.